Birdwatch Note
2024-11-05 05:50:43 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
レプリコンワクチンのコスタイベはベトナムの臨床試験で、プラセボ群にもワクチンを打つ前の有効性を評価する期間であるDay１～Day92において、各郡約8000人の参加者、ワクチン群５人死亡(コロナ死１)、プラセボ群１６人死亡（コロナ死９）という結果でした(全ての死亡は接種との因果関関係は認められず)。なので、治験では、健康を守っていた事に注意が必要です。 下記のpdf28pが日本語資料 https://web.archive.org/web/20240120232711/https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_2.pdf#page=28 下記が論文です。 https://www.nature.com/articles/s41467-024-47905-1/tables/2 この研究では評価項目に死亡はなく、有意差解析はされていませんが、この差が単純なオッズ比の解析ではゆうに有意差に達していることがわかります。 https://www.medcalc.org/calc/odds_ratio.php
Written by 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1853610642500100412
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1853676298260103374
- noteId - 1853676298260103374
- participantId -
- noteAuthorParticipantId - 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE Participant Details
- createdAtMillis - 1730785843802
- tweetId - 1853610642500100412
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 1
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- レプリコンワクチンのコスタイベはベトナムの臨床試験で、プラセボ群にもワクチンを打つ前の有効性を評価する期間であるDay１～Day92において、各郡約8000人の参加者、ワクチン群５人死亡(コロナ死１)、プラセボ群１６人死亡（コロナ死９）という結果でした(全ての死亡は接種との因果関関係は認められず)。なので、治験では、健康を守っていた事に注意が必要です。 下記のpdf28pが日本語資料 https://web.archive.org/web/20240120232711/https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_2.pdf#page=28 下記が論文です。 https://www.nature.com/articles/s41467-024-47905-1/tables/2 この研究では評価項目に死亡はなく、有意差解析はされていませんが、この差が単純なオッズ比の解析ではゆうに有意差に達していることがわかります。 https://www.medcalc.org/calc/odds_ratio.php
Note Ratings
| rated at | rated by | |
| 2024-11-06 00:23:21 -0600 | Rating Details | |
| 2024-11-05 15:19:29 -0600 | Rating Details | |
| 2024-11-05 07:53:31 -0600 | Rating Details | |
| 2024-11-05 07:10:09 -0600 | Rating Details | |
| 2024-11-05 06:51:34 -0600 | Rating Details | |
| 2024-11-05 05:37:30 -0600 | Rating Details | |
| 2024-11-05 04:47:30 -0600 | Rating Details | |
| 2024-11-05 03:53:19 -0600 | Rating Details | |
| 2024-11-05 03:52:09 -0600 | Rating Details | |
| 2024-11-05 03:22:09 -0600 | Rating Details | |
| 2024-11-05 03:12:46 -0600 | Rating Details | |
| 2024-11-05 03:10:06 -0600 | Rating Details | |
| 2024-11-05 03:01:03 -0600 | Rating Details | |
| 2024-11-05 01:54:09 -0600 | Rating Details | |
| 2024-11-05 01:25:20 -0600 | Rating Details | |
| 2024-11-05 01:25:01 -0600 | Rating Details | |
| 2024-11-05 01:07:26 -0600 | Rating Details | |
| 2024-11-05 00:46:51 -0600 | Rating Details | |
| 2024-11-05 00:42:01 -0600 | Rating Details | |
| 2024-11-05 00:39:42 -0600 | Rating Details | |
| 2024-11-05 00:37:28 -0600 | Rating Details | |
| 2024-11-05 00:30:20 -0600 | Rating Details | |
| 2024-11-05 00:27:18 -0600 | Rating Details | |
| 2024-11-05 00:26:16 -0600 | Rating Details | |
| 2024-11-05 00:25:56 -0600 | Rating Details | |
| 2024-11-05 00:15:58 -0600 | Rating Details | |
| 2024-11-05 00:13:47 -0600 | Rating Details | |
| 2024-11-05 00:13:17 -0600 | Rating Details | |
| 2024-11-05 00:11:27 -0600 | Rating Details | |
| 2024-11-05 00:08:47 -0600 | Rating Details | |
| 2024-11-05 00:07:28 -0600 | Rating Details | |
| 2024-11-05 00:01:41 -0600 | Rating Details | |
| 2024-11-04 23:57:16 -0600 | Rating Details | |
| 2024-11-04 23:56:33 -0600 | Rating Details | |
| 2024-11-07 08:57:06 -0600 | Rating Details | |
| 2024-11-05 10:18:01 -0600 | Rating Details | |
| 2024-11-05 09:45:30 -0600 | Rating Details | |
| 2024-11-05 06:54:09 -0600 | Rating Details | |
| 2024-11-05 05:36:29 -0600 | Rating Details | |
| 2024-11-05 04:34:04 -0600 | Rating Details | |
| 2024-11-05 03:25:19 -0600 | Rating Details | |
| 2024-11-05 03:20:27 -0600 | Rating Details | |
| 2024-11-05 02:28:10 -0600 | Rating Details | |
| 2024-11-05 01:43:48 -0600 | Rating Details | |
| 2024-11-05 01:36:05 -0600 | Rating Details | |
| 2024-11-05 01:21:32 -0600 | Rating Details | |
| 2024-11-05 01:17:38 -0600 | Rating Details | |
| 2024-11-05 01:14:44 -0600 | Rating Details | |
| 2024-11-05 01:02:14 -0600 | Rating Details | |
| 2024-11-05 00:58:49 -0600 | Rating Details | |
| 2024-11-05 00:33:45 -0600 | Rating Details | |
| 2024-11-05 00:18:22 -0600 | Rating Details | |
| 2024-11-07 17:04:35 -0600 | Rating Details | |
| 2024-11-07 09:03:06 -0600 | Rating Details | |
| 2024-11-05 09:06:35 -0600 | Rating Details | |
| 2024-11-05 06:18:08 -0600 | Rating Details | |
| 2024-11-05 04:38:33 -0600 | Rating Details | |
| 2024-11-05 03:22:05 -0600 | Rating Details | |
| 2024-11-05 02:46:01 -0600 | Rating Details | |
| 2024-11-05 02:24:34 -0600 | Rating Details | |
| 2024-11-05 02:17:40 -0600 | Rating Details | |
| 2024-11-05 00:24:36 -0600 | Rating Details | |
| 2024-11-05 00:22:14 -0600 | Rating Details | |
| 2024-11-05 00:14:56 -0600 | Rating Details | |
| 2024-11-05 00:01:47 -0600 | Rating Details |